Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiac Outcomes in Adults With Mitochondrial Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Three decades of heart transplantation: experience and long-term outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pressure-flow responses to exercise in aortic stenosis, mitral regurgitation and diastolic dysfunction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Gender- and Age-Specific Rates of Heart Failure and other Adverse Cardiovascular Outcomes in Systemic Sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Bilateral carpal tunnel syndrome (CTS) is a common extracardiac manifestation of amyloidosis and usually predates overt cardiac amyloidosis (CA) by several years. Screening studies on patients undergoing CTS surgery have shown a low yield of CA (2.0%), but high prevalence of amyloid in the carpal ligament. The proportion of patients with amyloid in the carpal ligament who later develop CA is unknown.

OBJECTIVES: The authors sought to investigate the prevalence of undiagnosed CA 5 to 15 years after surgery for bilateral CTS.

METHODS: Using national registries, the authors identified subjects aged 60 to 85 years with prior CTS surgery, where the first procedure on the second wrist was performed 5 to 15 years earlier. Invitations to participate in the study were sent by mail. Per international recommendations, the initial cardiac evaluation included echocardiography, 99mtechnetium-pyrophosphate scintigraphy, and assessment of monoclonal proteins in serum and urine.

RESULTS: A total of 250 subjects (35.7% of those invited) participated in the study. The median age was 70.4 years, and 50% were female. CA was diagnosed in 12 patients (4.8%; 95% CI: 2.5%-8.2%), and all cases were wild-type transthyretin amyloidosis (ATTRwt). The prevalence of ATTRwt in men was 8.8% (95% CI: 4.5%-15.2%; n = 11), and 21.2% (95% CI: 11.1%-34.7%) in male subjects ≥70 years with a BMI <30 kg/m2. All but 2 patients diagnosed with ATTRwt were in the lowest disease severity score (Mayo score).

CONCLUSIONS: Screening for CA in patients with prior surgery for bilateral CTS finds approximately 5% with early-stage transthyretin CA. The clinical yield was higher (>1 in 5) when focusing on nonobese men ≥70 years, showing potential for systematic screening.

OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind80
Udgave nummer10
Sider (fra-til)967-977
Antal sider11
ISSN0735-1097
DOI
StatusUdgivet - 6 sep. 2022

Bibliografisk note

Funding Information:
The study was funded by independent research grants from Erik og Susanna Olesens Almenvelgørende Fond, Pfizer, Arvid Nilssons Fond, Højmosegård-legatet, Frimodt-Heineke Fonden, and Hjertecentrets forskningsudvalg, Rigshospitalet (Dr Westin). Dr Fosbøl has received an independent research grant from Novo Nordisk Foundation, outside the submitted work. Dr Maurer has received grant support from NIH grants R01HL139671, R21AG058348, and K24AG036778; has been a consultant for Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, and Alnylam; and his institution has received clinical trial funding from Pfizer, Prothena, Eidos, and Alnylam. Dr Gustafsson has received personal fees from Abbott, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, and Orion Pharma outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Funding Information:
The authors thank Kirsten Arnaa, medical secretary, for management of grants; the cardiovascular research nurses for day-to-day assistance; Lesli Hingstrup Larsen for assistance with set-up of project biobank; and Lærke Marie Sidenius Nelson for assistance with planning the study and acquiring necessary approvals.

Publisher Copyright:
© 2022 American College of Cardiology Foundation

ID: 81291461